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OBJECTIVE: Assess TP53 functional mutations in the context of other biomarkers in 
advanced larynx cancer. 
STUDY DESIGN: Prospective analysis of pretreatment tumor TP53, HPV, Bcl-xL and 
cyclin D1 status in stage III and IV larynx cancer patients in a clinical trial. 
METHODS: TP53 exons 4-9 from 58 tumors were sequenced. Mutations were grouped 
using three classifications based on their expected function. Each functional group was 
analyzed for response to induction chemotherapy, time to surgery, survival, HPV status, 
p16INK4a, Bcl-xl and cyclin D1 expression.   
RESULTS: TP53 Mutations were found in 22/58 (37.9%) patients with advanced larynx 
cancer, including missense mutations in 13/58 (22.4%) patients, nonsense mutations in 4/58 
(6.9%), and deletions in 5/58 (8.6%).  High risk HPV was found in 20/52 (38.5%) tumors. 
A classification based on crystal Evolutionary Action score of p53 (EAp53) distinguished 
missense mutations with high risk for decreased survival from low risk mutations 
(p=0.0315).  A model including this TP53 classification, HPV status, cyclin D1 and Bcl-xL 
staining significantly predicts survival (p=0.0017).  
CONCLUSION: EAp53 functional classification of TP53 mutants and biomarkers predict 
survival in advanced larynx cancer.  (---179 words)  
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Larynx cancer is diagnosed in 12,260 patients in the United States each year, causing 3,630 
deaths.
1
 The high morbidity associated with the traditional surgical treatments led to the 
development of larynx sparing chemoradiotherapy regimens.
2,3
 Furthermore, in attempts to 
better classify patients for different treatment modalities and increase their survival, many 




The tumor suppressor p53 (TP53) is mutated in up to 60% of head and neck cancers in 
some series.
5
 It has a central role in determining cell fate in response to stressors. 
6-10
  The 
role of p53 as a prognostic biomarker in laryngeal cancer is controversial. Some studies 
show an association of p53 mutations with better sensitivity to chemotherapy,
11
 while 
others associate it with poor response.
12,13
  Almost 75% of the TP53 mutations reside in the 
DNA-binding domain, and more than 30% are in one of six “hotspot” codons. These 
mutations can promote cancer development. Thus, analysis based primarily on protein 
function is appropriate in assessing clinical outcome linked to p53 mutants, rather than only 
on its expression, as frequently done in the past. Functional classifications of p53 can be 
based on Evolutionary Action score of TP53 (EAp53),
14
 yeast based transcriptional 
activity, 
15
 and published gain of function (GOF)  mutations. 
 
In larynx cancer Bcl-xl and cyclin D1 are predictors of response to therapy and survival 
that are linked to p53 status. 
4,16
 Bcl-xl is an anti-apoptotic protein member of the Bcl-2 
family, 17-19 that inactivates pro-apoptotic proteins at the mitochondrial membrane. 19,20 
Cyclin D1 phosphorylates and inactivates RB, allowing cell cycle progression.  
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Human papillomaviruses (HPV) studies in laryngeal cancer have been limited to recurrent 
laryngeal papillomatosis, which is caused by infection with low risk HPV types 6 and 11.
21
  
High-risk HPV (hrHPV), especially HPV16, has become increasingly common in head and 
neck cancer.
22-28
  In the current study we assess the role of hrHPV, TP53 functional 
classifications, Bcl-xl and cyclin D1 each as single variable factoring outcome, and as part 
of a multivariable model for advanced larynx cancer outcome.   
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The UMCC9520 larynx sparring cancer trial enrolled 97 patients with stage III and IV 
squamous cell carcinoma of the larynx. Adequate pretreatment biopsy tissue was available 





Tissue Handling and DNA Extraction  
Tumor tissue was obtained from formalin fixed paraffin embedded pre-treatment biopsies.  
A head and neck pathologist marked representative areas of tumor. Two cores were taken 
from the marked areas using a 20G needle. DNA was extracted using the QiaAmp DNA 
Mini Kit (Qiagen, Valencia, California, USA). DNA quantity and quality were 
corroborated with UV-Vis spectrophotometer using a NanoDrop ND-1000 (NanoDrop 
Technologies, Wilmington, DE, USA).   
 
TP53 Sequencing 
TP53 mutations were assessed by PCR amplification of exons 4-9 and subsequent DNA 
sequencing. Seven pairs of primers were used (Supplementary Table I) with AmpliTaq 
DNA Polymerase as indicated by manufacturer (Invitrogen, Life Technologies, NY, USA). 
Amplification was performed at 95°C for 10 minutes, 36 cycles of 95°C for 30 seconds, 
60°C for 30 seconds, 72°C for 45 seconds and a final extension at 72°C for 10 minutes. The 
amplicons were examined with electrophoresis in a 1.5% agarose gel, purified using the 
Wizard SV Gel and PCR Clean-Up System (Promega Corporation, WI, USA) and 
submitted to the University of Michigan DNA Sequencing Core for bi-directional 
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sequencing. Mutations were confirmed with a second independent PCR reaction and 
sequencing. 
 
TP53 Mutant Classifications 
Three classifications designed to classify TP53 single base pair mutations (point mutations) 
were studied. The EAp53 classification that was designed and validated for head and neck 
cancers
14
, scores TP53 mutations as high risk mutations (H) and low risk mutations (L) 
obtained through a computational algorithm based on evolutionary sensitivity and amino 
acid conservation. Tumors without mutations were designated as wild type TP53 (W). 
Insertion/deletions were not scored. 
 
The p53 transactivation activities (TAs) classification is based on reporter gene activity 
placed under the control of eight p53 response elements (p53-RE) in yeast models
15
. TAs 
were measured as a percentage of wild type p53 TA and classified as “supertrans”(median 
TA above 140%), “functional”(median TA of 76-140%), “partially functional”(median TA 




The p53 mutant gain of function (GOF) classification is compared to mutants with no 
evidence of gain of function (NE-GOF) and wild type (W) TP53. P53 GOF mutations have 
been defined as those with activities independent and unrelated to wild type protein
15
. 
These activities were demonstrated by RNAi silencing or direct transfection of the mutant 
TP53.
30
 To identify GOF mutants a literature search of PubMed without language 
limitation was performed using the search terms “mutant p53” and “gain of function”. 
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DNA samples from the pretreatment biopsies were analyzed for the presence of high risk 




Bcl-xl, Cyclin D1 and p16INK4a Immunohistochemistry 
Staining intensity (scale: 1: none, 2: weak, 3: moderate and 4: strong) and proportion (scale 
1: <5% staining, 2: 5-20% staining, 3: 21-50% staining and 4: 51-100% staining) were 
assessed by immunohistochemistry using a tissue microarray and scored by a head and 





Associations between TP53 groups and clinical characteristics were assessed using χ2 
statistics.  Correlations with induction chemotherapy response, overall survival (OS), 
disease-specific survival (DSS) and time to indication for surgery (TIS) were tested by 
log-rank tests, and logistic and Cox proportional hazards regression models. Time to 
event outcomes (OS, DSS, TIS) were measured from date of diagnosis. For illustration in 
figures, Bcl-xl and Cyclin D1 intensity scores were grouped as “no (1)”, “low (2)” and 
“high (3 or 4)”. Multivariable analyses controlling for stage, smoking and hrHPV were 
performed using logistic and Cox proportional hazards models. Variables tested 
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included: TP53 mutational status, presence of hrHPV DNA, Bcl-Xl and CyclinD1 
expression.  
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TP53 sequence and clinical data were obtained from a previously published study.
3
 Basic 
clinical and tumor characteristics are shown in Table 1. 
 
TP53 Mutants 
Of the 97 eligible patients, TP53 gene was sequenced in 58. Of these, 22 tumors contained 
TP53 mutations. Five (8.6%) had deletions that were not classifieable. 53 patients classified 
had either wild type TP53 36/53 (68%) or single base changes (17/53 (32%)) corresponding 
to missense in 13/53 (24.5%), or non-sense mutations in 4 (7.5%). No insertions were 
found. A TP53 missense mutational spectrum is presented in Supplementary Table II. 
Bivariate associations were tested for each p53 classification with age, T stage, N stage, 
smoking and HPV. The EAp53 classification
14
 revealed a significant association of high 
risk (H) mutations and node positive tumors (p=0.03; Table 2). Seven (53.8%) of the 13 
missense mutations were classified as GOF.  No significant associations with clinical 
parameters were found for GOF or transactivation classifications, low risk mutations (L) 
and wild type (W). 
 
HPV and p16INK4a  
Tumor DNA from 52 patients was analyzed with the multiplex HPV PCR-MassArray 
assay
25
. High risk HPV was identified in 20/52 (38.5 %) tumors; 19/20 had HPV16 and one 
had HPV 18.  Of the HPV positive tumors 15/20 (75%) had wild type TP53 (consistent 
with HPV driven carcinogenesis), 3/20 (15%) had high risk TP53 mutations and 2/20 
(10%) had TP53 deletion (questionable for HPV carcinogenesis). HPV PCR-MassArray 
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negative tumors presented a WT TP53 only in 53% (16/30) cases.  Sixteen HPV PCR-
MassArray positive samples were assessed for p16INK4a status; 31% (5/16) were 
p16INK4a positive.  While all HPV+/p16INK4a+ tumors (5/5) had a WT TP53, only 64% 
(7/11) of the HPV+/p16INK4a- presented a WT TP53.  
 
A total of 46 tumors were stained for p16INK4a with 26% (12/46) been positive. From the 
12 p16INK4a positive samples only 42% (5/12) were HPV PCR-MassArray positive. The 
p16INK4a and HPV PCR-MassArray results were not concordant in larynx cancer (Pearson 
correlation coefficient Rho=0.09). 
 
TP53 Mutants and Induction Chemotherapy  
Thirty-eight of the 58 patients (66%) responded to induction chemotherapy (tumor volume 
decrease greater than 50%). Multivariable logistic regression models with different models 
including T stage and N stage separately, overall stage, HPV, and smoking were run. No 
significant predictors of response to induction chemotherapy were found in any of the TP53 
classifications.  
 
TP53 Mutants and Survival 
Of the 58 patients with a median follow up of 95 months, the Kaplan-Meier estimates for 
overall survival at 1, 2, and 5 years were 90%, 83% and 67% respectively. DSS estimates 
were 91%, 86%, 80% respectively. 
 
Using the EAp53 classification and univariate analysis (log-rank tests), we find a 
significant DSS difference between strata (p=0.026; Figure 1). Pairwise, the difference 
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between the H vs. L groups was significant (p=0.027). The differences between H vs W 
(p=0.188) and L vs W (p=0.988) groups were not statistically significant. Using a Cox 
model after controlling for T stage, N stage and HPV status the effect of p53 mutation was 
no longer significant (p=0.114). No significant differences were observed for DSS using 
the yeast assay based classification (p=0.603, log-rank; p=0.887 Cox) nor GOF 
classification (p=0.096 log-rank; p=0.130 Cox). Interestingly there was a trend for the GOF 
mutations to do better.  
 
TP53 Mutants and Time to Surgery  
Time to indication for surgery (TIS) was evaluated for the TP53 classifications. No 
significant differences in TIS were found between groups using the EAp53, yeast 
transcriptional assay based nor GOF classifications (p=0.654, p=0.394 and p=0.835 
respectively). After controlling for stage, smoking and HPV status the differences were still 
not significant (p=0.667; p=0.245; p=0.874 respectively). 
 
HPV, p16INK4a, Bcl-xL and cyclin D1: Effects on the EAp53 Classification and Survival 
The role of HPV, p16INK4a, Bcl-xL and cyclin D1 in the EAp53 classification was 
assessed. As a single variable, the presence of HPV did not reach significance (log-rank 
p=0.38) When separating the HPV positive tumors by p16INK4a status we found that the 
patients with HPV+/p16INK4a+ tumors tended to have a better DSS compared to the 
HPV+/p16INK4a- and HPV negative. This difference did not reach statistical significance 
(long-rank p=0.4037 and p=0.3506 respectively; Figure 2A). No patients with 
HPV+/p16INK4a+ tumors die due to cancer.  By including only the HPV positive cases 
with WT TP53 we observed that HPV positive WT TP53 patients tended to have better 
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DSS than the HPV negative patients. This difference did not reach statistical significance 
(p=0.195, Figure 2B). 
 
We found no evidence of an association between Bcl-xL intensity in different TP53 groups. 
In multivariable analysis, Bcl-xL expression displayed a trend for poorer DSS (p=0.075, 
Table 3). By plotting the DSS of the TP53 groups and sorting out the WT TP53 based on 
their biomarker status, we found no significant difference across Bcl-xL staining intensities. 
However, the group with WT TP53 and no expression of Bcl-xL had no deaths due to 
cancer (Figure 2C.). 
 
Alone cyclin D1 was associated with poor DSS (HR 2.4, p=0.010 Cox). When sorting the 
wild type TP53 by cyclin D1 staining intensity we found that high cyclin D1 staining was a 
predictor of poor survival compared with low or no cyclin D1 staining (p=0.051 and 
p=0.044 respectively; Figure 2D.)  Cyclin D1 showed a trend (p=0.096) for higher intensity 
in the “High Risk” group of p53 mutations. 
 
Multivariable Model for Prediction of Survival 
A model with Bcl-xL, cyclin D1, EAp53 classification and hrHPV status was highly 
significant as a prognostic model for disease specific survival (DSS) (p=0.002, likelihood 
ratio test; Table 3). A full model including EAp53 classification of TP53, Bcl-xL intensity, 
cyclin D1 intensity, stage, smoking status and HPV status was also performed 
(Supplementary Table III). This model was significant for modeling DSS (p=0.011), 
although a backward selection algorithm suggested dropping stage and smoking for a better 
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model. We found no significant models for induction chemotherapy response or to time to 
indication for surgery.  
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Three classifications for TP53 mutations were analyzed.  Only the EAp53 classification
14
 
based on mutant TP53 transcriptional activity showed clinical significance. This 
classification predicted DSS (p=0.026). In this clinical trial, patient selection through 
induction chemotherapy resulted in larynx preservation in 70% of patients and DSS of 
87%.
3
 Although patient survival was improved, there was still a subset of patients with 
poor outcome. The EAp53 classification has potential to identify this subset of patients.  
 
Bivariate associations were tested for EAp53 classification with age, T stage, N stage, 
smoking status, hrHPV, Bcl-xL and cyclin D1 staining. Of interest, high risk mutations 
found by EAp53 classification were associated with lymphatic metastasis at presentation 
(p=0.03) and a trend for high expression of cyclin D1 (p=0.096). It is known that node 
positive patients have poorer survival.
31
 Therefore, EAp53 classification could potentially 
guide therapeutic approaches such as neck dissection, neck irradiation or the addition of 
chemotherapy to radiation treatment. More aggressive treatment to the neck of patients with 
high risk TP53 mutations could improve patient outcome.  We also found a trend for high 
risk TP53 mutants to have high expression of cyclin D1. Cyclin D1 was previously found 
to be associated with overall and disease specific survival.
4
 We propose a mechanism in 
which cyclin D1 overexpression is unchecked by defective p53. High risk TP53 mutations 
have a lower expression of BTG2 (B-cell Translocation Gene 2) protein compared to their 
WT and low risk counterparts.
14
 BTG2 inhibits cyclin D1 transcription.
32,33
 Thus, its low 
expression is a likely mechanism for cyclin D1 overexpression.  Furthermore, cyclin D1 
itself could be constitutively overexpressed by dysregulation in the β-catenin
34,35
, 
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RAS/MAPK or IP3K pathways
36
. The EAp53 classification and cyclin D1 have proven to 
be powerful predictors of survival in advanced laryngeal cancer patients, but further studies 
are needed to characterize the cellular mechanisms by which these markers interact and 
affect survival in this type of cancer. 
 
GOF mutations affect important cellular activities like proliferation, apoptosis, 
chemoresistance, metabolism, cell to cell interactions or cytoskeleton conformation.
30
 Only 
(7/58) 12% of the sequenced patients had a TP53 GOF mutation.  These showed no impact 
on response to induction chemotherapy, time to surgery or survival.  We grouped all GOF 
mutations together. More specific classification of GOF mutations based on the cellular 
functions altered could offer a better understanding of how these mutations affect patient 
outcome.  Larger studies and a more comprehensive GOF classification are needed for 
assessment of their impact in laryngeal cancer. 
 
The proportion of tumors with mutant TP53 22/58, (37.9%) was lower than expected 
37
 
TP53 mutations are uncommon in HPV-positive tumors
38
. The low rate of TP53 mutations 
in this study is consistent with the high proportion of hrHPV positive larynx tumors 20/52 
(38.5%) we found. This is also consistent with previous reports of HPV in up to 25% of 
laryngeal carcinomas
39,40
 and the increasing frequency of HPV-related head and neck 
cancers generally.
41,42
  A recent report from the Tissue Cancer Genome Atlas (TCGA) head 
and neck cancer group included 72 larynx cancer cases. From these 66/72 (91.6%) have 
mutated TP53 and only 5/72 (7%) are HPV PCR-MassArray positive.
43
  Patient selection 
could be causative of the discrepancy found between the studies. While in the TCGA study 
samples were collected without regard to neither disease stage nor patient functional status, 
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in our study patients where part of a clinical trial and were selected with a good functional 
status and an advanced stage of disease (Stage III and IV).
3,43
  Differences in geographical 
distribution of the patients could be another factor affecting the HPV detection rates, as 




The biology of the HPV positive tumors was assessed using p16INK4a 
Immunohistochemistry. P16INK4a status did not correlate with HPV status (Rho=0.09), 
showing a dichotomy of HPV related larynx cancer. All HPV positive tumors with 
p16INK4a positive staining presented a WT TP53 and showed a better DSS with cero 
deaths caused by cancer. These HPV related tumors show characteristics of the typical 
HPV E6 and E7 driven cancers. A different subset of HPV positive tumors with p16INK4a 
negative staining did not show a clear correlation with TP53 mutational status and patients 
presented a DSS similar to the HPV negative patients (Figure 2A). Further studies 
addressing other mechanisms of HPV carcinogenesis like viral DNA integration, 
methylation profiling, miRNA profiling and characterization of other HPV related cellular 




 analyzing the Department of Veteran’s Affairs Laryngeal Cancer Trial,
2
 
found that low Bcl-xL and high p53 staining were predictors of larynx preservation in 
patients treated with induction chemotherapy followed by definitive radiation.  Here we 
found no significant effect of Bcl-xL on clinical outcome although in multivariable 
analysis, a trend was noted for poorer disease specific survival to be associated with Bcl-xL 
expression.  The association with organ preservation was not explored in this analysis.  It is 
interesting to note that among WTp53 patients with no Bcl-xL expression, no tumor 
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failures were seen. We observed similar trend to improved survival with Bcl-xL expression 
in the VA Study.  Both studies gave induction chemotherapy(cisplatin 100 mg/m2 on day 1 
and fluorouracil 1,000 mg/m2/d for 5 days).  In the VA study tumor response was assessed 
after two cycles of induction and responders went on to an additional cycle of 
chemotherapy followed by radiotherapy alone
2
.  In contrast, in UMCC9520 a single round 
of the same induction therapy was followed by response assessment and either immediate 
surgery/RT (non-responders) or radiotherapy with concurrent cisplatin (100 mg/m2) given 
on day 1, 22, 43.
3
 The addition of concurrent cisplatin to radiation in UMCC9520, could 
change the association of  Bcl-xL expression as a biomarker of outcome.  Recent studies 
suggest that cisplatin can activate extrinsic apoptotic pathways, induce necrosis,
46
 or cell 
senescence.
47
  In these scenarios cell death is no longer completely dependent on the 
intrinsic mitochondrial apoptotic machinery,
48
 which could explain loss of power for Bcl-
xL as a predictive biomarker.  Nonetheless, the importance of a functional intrinsic 
apoptotic pathway in the response to chemoradiotherapy is evidenced by the fact that in our 
study, patients whose tumor did not stain for the apoptotic inhibitor Bcl-xL and had WT 
TP53 did not die due to cancer (Figure. 3C.). 
 
We constructed a model for the prediction of disease specific survival based on a 
combination of biomarkers and clinical characteristics. The model including classification 
of TP53, Bcl-xL intensity, cyclin D1 intensity, stage, smoking status and HPV status was 
able to predict survival (p=0.011). By including only variables with a strong predictive 
value (i.e. Bcl-xL, cyclin D1, p53 mutation classification and HPV status) we obtained a 
selected model that was highly significant for the prediction of disease specific survival 
(p=0.0017, Likelihood Ratio Test Table 4). In this model we can distinguish two types of 
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patients: high risk TP53 mutation was predictive of poor DSS, and low risk TP53 mutation 
was predictive of good DSS (p=0.026; Figure 1.).  In patients with WT TP53 high staining 
of cyclin D1 was predictive of poor DSS, while no/low staining for cyclin D1, no staining 
for Bcl-xL and HPV positivity were predictors of good DSS (Figure 2; Supplementary table 
IV).  Thus, treatment modalities targeting p53 and cyclin D1 could increase survival in 
advanced larynx cancer patients that fail to respond to current treatment. Novel targeted 
therapies like mutant p53 reactivating small molecules, mdm2 inhibitors, cyclin dependent 
kinase inhibitors or inhibitors of β-catenin, RAS/MAPK or IP3K pathways could 
potentially counteract these markers and offer better outcome.  The model should be tested 
in larger cohorts.  
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A functional classification of TP53 mutants based on EAp53 predicts DSS in advanced 
larynx cancer patients with mutant TP53. A high proportion of hrHPV related larynx 
cancers in this cohort reflects the epidemic of HPV related head and neck cancers. A 
dichotomy in the biology of hrHPV is observed in larynx cancer.  A model including Bcl-
xL staining, cyclin D1 staining, p53 mutation classification and HPV status was highly 
significant for predicting disease specific survival. High cyclin D1 expression and high risk 
TP53 mutations were associated with poor DSS.  New therapies targeting these pathways 
could benefit patients that fail to respond to current treatment modalities. 
 
Abstract to conclusion 3066 words 
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Fig. 1. Disease-Specific Survival for patients with advanced laryngeal cancer classified by TP53 
mutation type based on EAp53 as low risk mutations (L), high risk mutations (H) and wild type (W). 
 
 
Fig. 2. Disease-specific survival by (A) HPV status with HPV positives sorted by p16INK4a status, (B) 
by EAp53 classification with TP53 wild types sorted by HPV status, (C) by EAp53 classification with 
TP53 wild types sorted by Bcl-xL intensity staining, (D) by EAp53 classification with TP53 wild types 
sorted by cyclin D1 intensity staining and (WT, wild type; mut, mutation. Intensity staining scores: 
1=no, 2=low, 3 or 4=high). 
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Fig. 2. Disease-specific survival by (A) HPV status with HPV positives sorted by p16INK4a status, (B) by 
EAp53 classification with TP53 wild types sorted by HPV status, (C) by EAp53 classification with TP53 wild 
types sorted by Bcl-xL intensity staining, (D) by EAp53 classification with TP53 wild types sorted by cyclin 
D1 intensity staining and (WT, wild type; mut, mutation. Intensity staining scores: 1=no, 2=low, 3 or 
4=high).  
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Table 1: Patient and Tumor Characteristics 




Gender 58 Male 48 83% 
  Female 10 17% 
T stage 58 T2 5 9% 
  T3 30 52% 
  T4 23 40% 
N stage 58 N0 29 50% 
  N1 12 21% 
  N2 15 26% 
  N3 2 3% 
AJCC Stage 58 Stage III 24 41% 
  Stage IV 34 59% 
Smoking Status 58 Never 2 4% 
  Former 12 21% 
  Current 42 75% 
HPV 52
b 
Positive 20 39% 
  Negative 32 62% 
     
EAp53 Risk 
Classification 58 Wild Type P53 36 62% 
  Deletion 5 9% 
  High (H) 10 17% 
  Low  (L) 7 12% 
Yeast Assay 
Based 
Classification 58 Functional 38 66% 
  Deletion 5 9% 
  Partially functional 1 2% 
  Nonfunctional 14 24% 
Gain of 
Function (GOF) 
Classification 58 Wild type 37 64% 
  Deletion 5 9% 
  GOF Mutation 7 12% 
  No GOF Mutation 9 16% 
   Mean (std) 
Age (years)   57.2 (11.2) 
a). % may not add to 100 due to rounding. 
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Table 2: Nodal status, HPV and EAp53 Classification   



















Total 5 10 7 36 58 
      



















Total 4 9 6 33 52
a 
a). n=52 for HPV due to tissue availability. 
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Table 3: Cox Proportional Hazards Model Results from Selected Model for Prediction 
of Disease-Specific Survival  
 
Parameter  Value p-value Hazard Ratio 
95% Hazard Ratio 
Confidence Limits 
Cyclin D1   0.0325 3.782 1.117 12.803 
Bcl-xL   0.0751 0.307 0.084 1.127 
EAp53 Classification H vs. WT 0.0186 7.591 1.404 41.043 
EAp53 Classification L vs. WT ie. ie ie ie 
HPV Neg vs. Pos 0.0262 58.123 1.619 2086.187 
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SUPPLEMENTARY TABLES  
 
 
SUPPLEMENTARY TABLE I 
 TP53 Sequencing Primers 
    
Primer Primer Sequence 
    
p53 Exon 4.1 F 5´-CCCATCTACAGTCCCCCTTG -3´ 
p53 Exon 4.1 R 5’-GGTGTAGGAGCTGCTGGTG-3’ 
p53 Exon 4.2 F 5´- CTGAAGACCCAGGTCCAGATGAA  -3´ 
p53 Exon 4.2 R 5´- AACTGACCGTGCAAGTCACA -3´ 
p53 Exon 5.1 F 5´- CTTGTGCCCTGACTTTCAACTCTGTCTC -3´ 
p53 Exon 5.1 R 5´- CAGCGCCTCACAACCTCCGTCAT -3´ 
p53 Exon 5.2 F 5´- CTGTGCAGCTGTGGGTTGATTCCACACC -3´ 
p53 Exon 5.2 R 5´- TGGGCAACCAGCCCTGTCGTCTCTCCA -3´ 
p53 Exon 6 F 5´-CCAGGCCTCTGATTCCTCACTGATTGCTC-3´ 
p53 Exon 6 R 5´-GCCACTGACAACCACCCTTAACCCCTC-3´ 
p53 Exon 7 F 5´-GCCTCATCTTGGGCCTGTGTTATCTCC-3 
p53 Exon 7 R 5´-GGCCAGTGTGCAGGGTGGCAAGTGGCTC-3´ 
p53 Exon 8 F 5´-GTAGGACCTGATTTCCTTACTGCCTCTTGC-3´ 
p53 Exon 8 R 5´-ATAACTGCACCCTTGGTCTCCTCCACCGC-3´ 
p53 Exon 9 F 5´-CACTTTTATCACCTTTCCTTGCCTCTTTCC-3´ 
p53 Exon 9 R 5´-AACTTTCCACTTGATAAGAGGTCCCAAGAC-3´ 
Abbreviations: F, Forward; R, Reverse. 
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SUPPLEMENTARY TABLE II 
Mutational Spectrum of TP53 Point 
Mutations in Advanced Larynx Cancer  
Codon  Amino Acid Substitution 
157 Valine to phenylalanine 
158 Arginine to cysteine 
163 Tyrosine to cysteine 
167 Glutamine to stop codon 
180 Glutamic acid to stop codon 
193 Histidine to leucine 
205 Tyrosine to cysteine 
236 Tyrosine to cysteine 
244 Glycine to cysteine 
245 Glycine to valine 
245 Glycine to alanine 
249 Arginine to serine 
282 Arginine to tryptophan 
282 Arginine to tryptophan 
293 Glutamic acid to stop codon 
306 Arginine to stop codon 
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SUPPLEMENTARY TABLE III 
Hazards Ratio Estimates of a Full Model for Prediction of Disease-Specific 
Survival 
Parameter  Value p-value 
Hazard 
Ratio 
95% Hazard Ratio 
Confidence Limits 
Cyclin D1   0.0486 3.650 1.008 13.218 
Bcl-xL   0.1297 0.364 0.099 1.345 
EAp53 Classification H vs. WT 0.0247 9.109 1.324 62.653 
EAp53 Classification L vs. WT ie. ie ie ie 
Stage 3 vs. 4 0.8209 1.237 0.196 7.825 
Smoking Status N vs. C ie. ie ie ie 
Smoking Status F vs. C 0.6986 0.552 0.027 11.152 
HPV Neg vs. 
Pos 
0.0367 51.163 1.277 2050.548 
H=High risk mutation; L=Low risk mutation; WT=Wild type TP53; N=Nonsmoker; C=Current 
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SUPPLEMENTARY TABLE IV 
Pairwaise Comparison of Disease Specific Survival of Patients with WT TP53 
based on Cyclin D1 Staining, Bcl-xL Staining and HPV Status     





High risk p53 mut WT p53 high cyclinD1 0.0481 0.8264 0.9995 
High risk p53 mut WT p53 low cyclinD1 5.1372 0.0234 0.1558 
High risk p53 mut WT p53 no cyclinD1 5.4547 0.0195 0.1337 
Low risk p53 mut WT p53 high cyclinD1 4.6986 0.0302 0.192 
Low risk p53 mut WT p53 low cyclinD1 0.000165 0.9898 1 
Low risk p53 mut WT p53 no cyclinD1 0.0128 0.9098 1 
WT p53 high cyclinD1 WT p53 low cyclinD1 3.8075 0.051 0.2902 
WT p53 high cyclinD1 WT p53 no cyclinD1 4.0616 0.0439 0.2585 
WT p53 low cyclinD1 WT p53 no cyclinD1 0.00816 0.928 1 
High risk p53 mut WT p53 HPVneg 0.3689 0.5436 0.9298 
High risk p53 mut WT p53 HPVpos 5.0895 0.0241 0.1085 
Low risk p53 mut WT p53 HPVneg 1.3761 0.2408 0.6439 
Low risk p53 mut WT p53 HPVpos 0.2105 0.6464 0.9679 
WT p53 HPVneg WT p53 HPVpos 1.6797 0.195 0.5654 
High risk p53 mut WT p53 high BclxL 1.9906 0.1583 0.6206 
High risk p53 mut WT p53 low BclxL 1.9683 0.1606 0.6257 
High risk p53 mut WT p53 no BclxL 6.7551 0.0093 0.0705 
Low risk p53 mut WT p53 high BclxL 0.7854 0.3755 0.9021 
Low risk p53 mut WT p53 low BclxL 0.8046 0.3697 0.8981 
Low risk p53 mut WT p53 no BclxL 0.000206 0.9886 1 
WT p53 high BclxL WT p53 low BclxL 0.000088 0.9925 1 
WT p53 high BclxL WT p53 no BclxL 0.7683 0.3808 0.9056 
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